CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

Summary

This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as CBL0137, may work by binding to tumor cell deoxyribonucleic acid (DNA) to stop the cell from growing further.

Timeline

Start

2019-07-01

Primary completion

2024-01-16

Completion

2024-01-16

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual”

Drugs

Indications